Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

No one knows exactly why resistance to malaria drugs always emerges first in this remote western province of Cambodia, nestled in the Cardamom Mountains. “The reasons are as much social as biological,” says malariologist Tom Peto, who is here in this dusty, unremarkable-looking town battling the latest threat to global malaria control: multiple drug–resistant (MDR) malaria.

Young man behing a mosquito nest, in Southeast Asia
Migrant workers such as this man in Pailin, Cambodia, near the border with Thailand, are at especially high risk of contracting malaria. Jeffrey Lau

PAILIN, CAMBODIA—Whatever the reason, this is where it starts. Resistance to chloroquine surfaced here in the 1950s before sweeping through the wider Mekong region and then into India and Africa, causing millions of deaths. Sulfadoxine-pyrimethamine went next, in the 1960s. Mefloquine failed in the 1970s.

Then in late 2008 and 2009 came reports that rocked the malaria world: Artemisinin, the so-called wonder drug that has sent malaria deaths plummeting across the globe over the past decade, was losing its effectiveness here. That sparked global alarm and prompted an ultimately futile emergency plan to contain resistance in Cambodia before the last, best drug was lost.

Now, Pailin is the epicenter of what some say is the greatest threat yet to malaria control: the deadliest malaria parasite, Plasmodium falciparum, has become resistant not only to artemisinin, but to a key partner drug, piperaquine, or PPQ, that is used in combination with artemisinin and is critical to its success. The emergence of this MDR parasite is raising the specter of untreatable malaria in the Mekong region and perhaps beyond.

Similar stories

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.